Biomeme Stock

biomeme.comHealthcare / BioTech & PharmaFounded: 2012Funding to Date: $18.33MM

Biomeme is the developer of a platform that transforms your smartphone into a mobile lab for advanced DNA diagnostics and real-time disease surveillance.

Register To Buy and Sell Shares

For more details on financing and valuation for Biomeme, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Biomeme’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Biomeme.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Jesse vanWestrienen
Co-Founder & Lead Biologist
Marc DeJohn
Co-founder & Lead Engineer
Max Perelman
Co-Founder, President, Business Lead and Chief Executive Officer

Frequently Asked Questions About Biomeme’s Stock

Can you buy Biomeme’s stock?
Biomeme is not publicly traded on NYSE or NASDAQ in the U.S. To buy Biomeme’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Biomeme’s stock?
Yes, you can sell stock of a private company like Biomeme. Forge can help you sell your Biomeme stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Biomeme’s stock price?
Biomeme is a privately held company and therefore does not have a public stock price. However, you may access Biomeme’s private market stock price with Forge Data.
What is Biomeme’s stock ticker symbol?
Biomeme does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Experts discuss the game-changing potential of novel host response-based diagnostics to combat the global challenge of antimicrobial resistance (AMR)
Host response diagnostics, a novel approach that leverages the host-immune response to distinguish between viral and bacterial pathogens, is giving hope in the battle against antimicrobial resistance (AMR). This approach is being led by Biomeme, a company specializing in decentralized molecular diagnostics. The method allows healthcare providers to optimize antibiotic use and combat the rise of AMR.
Updated on: Apr 18, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.